Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Down 25.2% in December

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totaling 4,111,105 shares, a decrease of 25.2% from the December 15th total of 5,496,827 shares. Based on an average trading volume of 1,018,839 shares, the days-to-cover ratio is presently 4.0 days. Approximately 5.8% of the company’s stock are short sold. Approximately 5.8% of the company’s stock are short sold. Based on an average trading volume of 1,018,839 shares, the days-to-cover ratio is presently 4.0 days.

Insider Activity at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters acquired 6,459,973 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The stock was acquired at an average price of $1.20 per share, for a total transaction of $7,751,967.60. Following the completion of the acquisition, the insider owned 13,509,973 shares of the company’s stock, valued at approximately $16,211,967.60. This represents a 91.63% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $1.33, for a total transaction of $9,975,000.00. Following the completion of the transaction, the insider owned 6,459,973 shares in the company, valued at approximately $8,591,764.09. The trade was a 53.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.90% of the stock is owned by company insiders.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Millennium Management LLC raised its holdings in Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares during the period. Vanguard Group Inc. increased its position in Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock worth $4,386,000 after buying an additional 19,768 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 4.7% in the second quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock worth $3,241,000 after buying an additional 124,985 shares during the period. Bank of America Corp DE lifted its position in shares of Zentalis Pharmaceuticals by 117.1% during the 3rd quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock valued at $2,339,000 after buying an additional 835,466 shares in the last quarter. Finally, Tybourne Capital Management HK Ltd. lifted its position in shares of Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock valued at $1,715,000 after buying an additional 516,666 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $2.96 on Monday. The firm has a 50-day moving average of $1.68 and a 200 day moving average of $1.58. The company has a market cap of $213.86 million, a P/E ratio of -1.43 and a beta of 1.75. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $3.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.12. On average, equities research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on ZNTL. Weiss Ratings reiterated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Morgan Stanley lowered their price target on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 12th. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Finally, Wedbush reiterated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.53.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.